AV
Anushka Vilas Salvi
About Anushka Vilas Salvi
Data last updated:
Anushka Vilas Salvi is a Director at Nucleon Research Private Limited (since 2023) and Designated Partner at Nucleon Therapeutics Llp (since 2019). The companies operate in Professional Services and Travel and Hospitality. The largest current company by reported revenue is Nucleon Research Private Limited at ₹26.1 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Nucleon Research Private Limited U72100MH2023PTC402795 | Director | 12 May 2023 | 2023 | ₹26.1 Lakh (FY 2025) | Active |
| Nucleon Therapeutics Llp AAJ-2427 | Designated Partner | 20 Aug 2019 | 2017 | Active |
Board colleagues of Anushka Vilas Salvi
| Name | DIN | Company | Designation |
|---|---|---|---|
| Ananya Banerjee | 07821951 | Nucleon Research Private Limited | Director |
| Robin Banerjee | 00008893 | Nucleon Research Private Limited | Director |
| Rashmi Santosh Mahadik | 08407065 | Nucleon Therapeutics Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Anushka Vilas Salvi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anushka Vilas Salvi
Anushka Vilas Salvi currently holds 2 directorships: Nucleon Research Private Limited (Director, since 12 May 2023, revenue ₹26.1 Lakh (FY 2025)); Nucleon Therapeutics Llp (Designated Partner, since 20 Aug 2019).
Anushka Vilas Salvi was first appointed on 20 Aug 2019 as Designated Partner at Nucleon Therapeutics Llp. The most recent appointment on record is 12 May 2023 at Nucleon Research Private Limited.
The current boards of Anushka Vilas Salvi's companies include Ananya Banerjee (Nucleon Research Private Limited), Robin Banerjee (Nucleon Research Private Limited), Rashmi Santosh Mahadik (Nucleon Therapeutics Llp).